Principles and Biophysics of Dialysis

  • John A. Sargent
  • Frank A. Gotch


Intermittent dialysis therapy is used in chronic uremia to re-establish body water solute concentrations that cannot be achieved by the natural organ. In this sense, the dialyzer becomes an artificial kidney and it is through the transport of substances by this device that chemical and biophysical control consistent with continued survival is achieved. The chapter is organized as shown in Figure 1 and will consist of two basic lines of development:
  1. 1.

    Consideration of the dialyzer and its operating principles,

  2. 2.

    Consideration of the patient-dialyzer system with regard to solute control in intermittent dialysis therapy.



Hollow Fiber Dialysis Treatment Uremic Toxin Chronic Uremia Middle Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Michaels AS: Operating parameters and performance criteria for hemodialyzers and other membrane- separation devices. Trans Am Soc Artif Intern Organs 12: 387, 1966PubMedGoogle Scholar
  2. 2.
    Gotch FA, Autian J, Colton CK, Ginn HE, Lipps BJ, Lowrie EG: The Evaluation of Hemodialyzers. DHEW Publ no (NIH) 72–103: 7, 1971Google Scholar
  3. 3.
    Babb AL, Popovich RP, Christopher TG, Scribner BH: The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17: 81, 1971PubMedGoogle Scholar
  4. 4.
    Klein E: Membranes and materials evaluation. Proc 7th Annual Contractors’ Conf. Artif Kidney- Chronic Uremia Program NIAMDD edited by Krueger KK, DHEW publ no (NIH) 75–248:85, 1974Google Scholar
  5. 5.
    Gotch FA, Sargent JA, Keen ML, Seid MA, Foster R: Comparative treatment time with Kiil, Gambro and Cordis-Dow Kidneys. Proc Clin Dial Transpl Forum 3: 217, 1973Google Scholar
  6. 6.
    Model FS, Davis HJ, Gordon MG: Prepare and evaluate optimized hemodialysis membranes. Proc 8th Annual Contractors Conf Artif Kidney — Chronic Uremia Program NIAMDD edited by Mackey BB, DHEW publ no (NIH) 76–248:71, 1975Google Scholar
  7. 7.
    Klein E, Lindholm DD, Smith JK, Holland FF: Study of synthetic polypeptides for hemodialysis membranes. Proc 7th Annual Contractors’ Conf Artif Kidney — Chronic Uremia Program NIAMDD edited by Krueger KK, DHEW publ no (NIH) 75–248:75, 1974Google Scholar
  8. 8.
    Barbour BH, Bernstein M, Cantor PA, Fisher BS, Stone W Jr: Clinical use of NISR 440 polycarbonate membrane for hemodialysis. Trans Am Soc Artif Intern Organs 21: 144, 1975PubMedGoogle Scholar
  9. 9.
    Wolf AV, Remp DG, Kiley JE, Currie GD: Artificial kidney function: Kinetics of Hemodialysis. J Clin Invest 30: 1062, 1951PubMedCrossRefGoogle Scholar
  10. 10.
    Smith HW: The Kidney: Structure and Function in Health and Disease. New York, Oxford University Press, 1951, p 39Google Scholar
  11. 11.
    Gotch FA: Hemodialysis: Technique and kinetic considerations. Chapter 41 in The Kidney, edited by Brenner BM, Rector FC Jr, Philadelphia, WB Saunders Company, 1976, p 1673Google Scholar
  12. 12.
    Nolph KD, Nothum RJ, Mäher, JF: Effects of ultrafiltration on dialysance in commercially available coils. Kidney Int 2: 293, 1972PubMedCrossRefGoogle Scholar
  13. 13.
    Nolph KD, Nothum RJ, Maher JF: Ultrafiltration: A mechanism for removal of intermediate molecular weight substances in coil dialyzers. Kidney Int 6: 55, 1974PubMedCrossRefGoogle Scholar
  14. 14.
    Farrell PC, Babb AL: Estimation of the permeability of cellulosic membranes from solute dimensions and diffusivities.J Biomed Mater Res 7: 25, 1973Google Scholar
  15. 15.
    Bottomley S, Parsons FM, Broughton PMG: The dialysis of non-electrolytes through regenerated cellulose (Cuprophane). I. The effect of molecular size: J Appl Polym Sci 16: 2115, 1972CrossRefGoogle Scholar
  16. 16.
    Babb AL, Farrell PC, Uvelli DA, Scribner BH: Hemodialyzer evaluation by examination of solute molecular spectra. Trans Am Soc Artif Intern Organs 18: 98, 1972PubMedCrossRefGoogle Scholar
  17. 17.
    Popovich RP, Hlavinka DJ, Bomar JB, Moncrief JW, Decherd JF: The consequences of physiological resistances on metabolite removal from the patient — artificial kidney system. Trans Am Soc Artif Intern Organs 21: 108, 1975PubMedGoogle Scholar
  18. 18.
    French D: The Schardinger dextrins. Adv Carbohydrate Chem 12: 189, 1957Google Scholar
  19. 19.
    Horowitz HI: Uremic toxins and platelet function. Arch Intern Med 127–823, 1970Google Scholar
  20. 20.
    Cohen BD: Guanidinosuccinic acid in uremia. Arch Intern Med 126: 846, 1970CrossRefGoogle Scholar
  21. 21.
    Giovannetti S, Biagini M, Cioni L: Evidence that methyl guanidine is retained in chronic renal failure. Experientia 24: 341, 1968PubMedCrossRefGoogle Scholar
  22. 22.
    Schmidt EG, McElvain NS, Bowen JJ: Plasma amino acids and the ether soluble phenols in uremia. Am J Clin Path 20: 253, 1950PubMedGoogle Scholar
  23. 23.
    Gordon A, Bergström J, Fürst P, Zimmerman L: Separation and characterization of uremic metabolites in biologic fluids: A screening approach to the definition of uremic toxins. Kidney Int 7 (suppl): S45, 1975CrossRefGoogle Scholar
  24. 24.
    Giovannetti S, Barsotti G: Dialysis of methylguanidine. Kidney Int 6: 177, 1974PubMedCrossRefGoogle Scholar
  25. 25.
    Fürst P, Bergström J, Gordon A, Johnsson E, Zimmerman L: Separation of peptides of “middle” molecular weight from biological fluids of patients with uremia. Kidney Int 7 (suppl): S272, 1975Google Scholar
  26. 26.
    Funck-Brentano JL, Man NK, Sausse A, Zingraff J, Boudet J, Becker A, Cueille GF: Characterization of a 1100–1300 MW uremic neurotoxin. Trans Am Soc Artif Intern Organs 22: 163, 1976PubMedGoogle Scholar
  27. 27.
    Pitts RF: Physiology of the Kidney and Body Fluids. Chicago, Year Book Medical Publishers, Inc, 1968, p 181Google Scholar
  28. 28.
    Bartsch HJ: Handbook of Mathematical Formulas. Translated by Liebscher H, New York, Academic Press, 1974, p 139Google Scholar
  29. 29.
    Walser M, Bodenlos LJ: Urea metabolism in man. J Clin Invest 38: 1617, 1959PubMedCrossRefGoogle Scholar
  30. 30.
    Lowrie EG, Steinberg SM, Galen MA, Gagneux SA, Lazarus JM, Gottlieb MN, Merrill JP: Factors in the dialysis regimen which contribute to alterations in the abnormalities of uremia. Kidney Int 10: 409, 1976PubMedCrossRefGoogle Scholar
  31. 31.
    Kreyszig E: Advanced Engineering Mathematics New York, John Wiley and Sons, 1972, p 24, 147Google Scholar
  32. 32.
    Sokolnikoff IS, Redheffer RM: Mathematics of Physics and Modern Engineering. New York, McGraw Hill, 1958,p 23, 756Google Scholar
  33. 33.
    Giovannetti S, Maggiore Q: A low nitrogen diet with proteins of high biological value for severe chronic uremia. Lancet 1: 1000, 1964PubMedCrossRefGoogle Scholar
  34. 34.
    Shaw AB, Bazzard FJ, Booth EM, Nilwarangkur S, Berlyne GM: The treatment of chronic renal failure by modified Giovannetti diet. QJ Med 34: 237, 1965Google Scholar
  35. 35.
    Kerr DNR, Robson A, Elliott RW, Ashcroft R: Diet in chronic renal failure. Proc Roy Soc Med 60: 115, 1967PubMedGoogle Scholar
  36. 36.
    Franklin SS, Gordon A, Kleeman CR, Maxwell MH: Use of a balanced low-protein diet in chronic renal failure. JAMA 202: 477, 1967PubMedCrossRefGoogle Scholar
  37. 37.
    Kopple JD, Sorensen MK, Coburn JW, Gordon A, Rubini ME: Controlled comparison of 20 g and 40 g protein diets in the treatment of chronic uremia. Am J Clin Nutr 21: 553, 1968PubMedGoogle Scholar
  38. 38.
    Hewlett AW, Gilbert QO, Wickett AD: The toxic effects of urea on normal individuals. Arch Int Med 18: 636, 1916CrossRefGoogle Scholar
  39. 39.
    Grollman EF, Grollman A: Toxicity of urea and its role in the pathogenesis of uremia. J. Clin Invest 38: 749, 1959PubMedCrossRefGoogle Scholar
  40. 40.
    Wineman RJ, Sargent JA, Piercy L: The dietitian’s role in quantitative studies of dialysis therapy. J Am Diet Assoc 1978Google Scholar
  41. 41.
    Sargent JA, Gotch FA: The analysis of concentration dependence of uremic lesions in clinical studies. Kidney Int 1 (suppl): S35, 1975Google Scholar
  42. 42.
    Gotch FA, Sargent JA, Keen ML, Lee M: Individualized, quantified dialysis therapy of uremia. Proc Clin Dial Transpl Forum 4: 27, 1974Google Scholar
  43. 43.
    Gotch FA, Farrell PC, Sargent JA: Theoretical considerations on molecular transport in dialysis and sorbent therapy for uremia. J Dialysis 1: 105, 1976Google Scholar
  44. 44.
    Dombeck DH, Klein E, Wendt RP: Evaluation of two pool model for predicting serum creatinine levels during intra and interdialytic periods. Trans Am Soc Artif Intern Organs 21: 117, 1975PubMedGoogle Scholar
  45. 45.
    Sanfelippo ML, Hall DA, Walker WE, Swenson RS: Quantitative evaluation of hemodialysis therapy using a simple mathematical model and a programmable pocket calculator. Trans Am Soc Artif Intern Organs 21: 125, 1975PubMedGoogle Scholar
  46. 46.
    Katz MA, Hull AR: Transcellular creatinine disequilibrium and its significance in hemodialysis. Nephron 12: 171, 1974PubMedCrossRefGoogle Scholar
  47. 47.
    Bleiler RE, Schedl HP: Creatinine excretion: variability and relationships to diet and body size. J Lab Clin Med 59: 945, 1962PubMedGoogle Scholar
  48. 48.
    Walser M: The conservative management of the uremic patient. In The Kidney, edited by Brenner BM, Rector FC Jr, Philadelphia, WB Saunders Company, 1976, p 1618Google Scholar
  49. 49.
    Gotch FA, Sargent JA, Keen ML, Lam M, Prowitt M, Grady M, Schoenfeld P, Borah M, Wolfson M, Piercy L, Leddy E, Humphreys M: The solute kinetics of intermittent dialysis therapy. Second Annual Report to Artificial Kidney — Chronic Uremia Program NIAMDD 1976, p 40 (unpublished)Google Scholar
  50. 50.
    Swan RC, Pitts RF: Neutralization of infused acid by nephrectomized dogs. J Clin Invest 34: 205, 1955PubMedCrossRefGoogle Scholar
  51. 51.
    Gotch FA, Borah M, Keen M, Sargent J, Schoenfeld P, Ayus C, Humphreys M: The solute kinetics of intermittent dialysis therapy (IDT). Proc 10th Annual Contractors Conf Artif Kidney - Chronic Uremia Program NIAMDD 1977, p 104Google Scholar
  52. 52.
    Graefe U, Milutinovich J, Follette W, Vizzo J, Scribner BH: Effect of high efficiency dialysis on acid-base balance and patient “well being”. Am Soc Nephrol (Abstracts) 9: 31, 1976Google Scholar
  53. 53.
    Mion CM, Hegstrom RM, Boen ST, Scribner BH: Substitution of sodium acetate for sodium bicarbonate in the bath fluid for hemodialysis. Trans Am Soc Artif Intern Organs 10: 110, 1964PubMedGoogle Scholar
  54. 54.
    Mahler HR, Cordes EH: Biological Chemistry, New York, Harper and Row, 1971, p 595Google Scholar
  55. 55.
    Schwartz WB, Jenson RL, Relman SA: The disposition of acid administered to sodium-depleted subjects: the renal response and the role of the whole body buffers. J Clin Invest 33: 587, 1954PubMedCrossRefGoogle Scholar
  56. 56.
    Schwartz WB, Orning KJ, Porter R: The internal distribution of hydrogen ions with varying degrees of metabolic acidosis. J Clin Invest 36: 373, 1957PubMedCrossRefGoogle Scholar
  57. 57.
    Gotch FA, Borah MF, Keen ML, Lam MA, Prowitt MH, Sargent JA: The solute kinetics of intermittent dialysis therapy. Third Annual Report to Artificial Kidney — Chronic Uremia Program NIAMDD 1977, p 48 (unpublished)Google Scholar
  58. 58.
    Garella S, Dana CL, Chazan JA: Severity of metabolic acidosis as a determinant of bicarbonate requirements. N Engl J Med 289: 121, 1973PubMedCrossRefGoogle Scholar
  59. 59.
    Weiner MW: The role of acetate in dialysate for hemodialysis. An investigation using biochemical and radio-spirometric techniques. First Annual Report to Artificial Kidney — Chronic Uremia Program NIAMDD 1976, p 108 (unpublished)Google Scholar
  60. 60.
    Krebs HA: The biochemical lesion in ketosis. Arch Intern Med 107: 119, 1961CrossRefGoogle Scholar
  61. 61.
    Lundquist F: Production and utilization of free acetate in man. Nature 193: 579, 1962PubMedCrossRefGoogle Scholar
  62. 62.
    Sargent JA: The role of acetate in acid-base correction during hemodialysis treatment. Doctoral Dissertation University of California, Berkeley, 1976Google Scholar
  63. 63.
    Burzynski SR: Biologically active peptides in human urine: I. Isolation of a group of medium size peptides. Physiol Chem Physics 5: 437, 1973Google Scholar
  64. 64.
    Shinaberger JH, Miller JH, Rosenblatt MG, Gardner PW, Carpenter GW, Martin FE: Clinical studies of “low flow” dialysis with membranes highly permeable to middle weight molecules. Trans Am Soc Artif Intern Organs 18: 82, 1972PubMedCrossRefGoogle Scholar
  65. 65.
    Rattazzi T, Wathen R, Comty C, Raij L, Leonard A, Shapiro F: The comparison of low flow (QD 200) to regular flow (QD 500) dialysis. Trans Am Soc Artif Intern Organs 20: 402, 1974Google Scholar
  66. 66.
    Scribner BH, Babb AL: Evidence for toxins of middle molecular weight. Kidney Int 7 (suppl): S349, 1975Google Scholar
  67. 67.
    Ginn HE, Teschan PE, Walker PJ, Bourne JR, Macalyne F, Ward JW, McLain LW, Johnson HB, Hamel B; Neurotoxicity in uremia. Kidney Int 1 (suppl): S357, 1975Google Scholar
  68. 68.
    Tenckhoff H, Curtis FK: Experience with maintenance peritoneal dialysis in the home. Trans Am Soc Artif Intern Organs 16: 90, 1970PubMedGoogle Scholar
  69. 69.
    Bell RL, Curtis FK, Babb AL: Analog simulation of the patient — artificial kidney system. Trans Am Soc Artif Intern Organs 11: 183, 1965PubMedCrossRefGoogle Scholar
  70. 70.
    Popovich RP: Physiological transport parameters in patients in peritoneal and hemodialysis. First Annual Report to Artificial Kidney — Chronic Uremia Program NIAMDD 1974 (unpublished)Google Scholar
  71. 71.
    Gotch FA, Sargent JA, Peters JH: Studies on the molecular etiology of uremia. Kidney Int 7 (suppl): S276, 1975Google Scholar
  72. 72.
    Henderson LW, Stone RA, Ford CA, Lysaght MJ: Blood pressure control with hemodiafiltration. Proc 10th Annual Contractors’ Conf Artif Kidney — Chronic Uremia Program NIAMDD 1977, p 110 (in press)Google Scholar
  73. 73.
    Funck-Brentano JL, Man NK, Sausse A, Cueille G, Zingraff J, Drueke T, Jungers P, Billon JP: Neuropathy and “middle” molecule toxins. Kidney Int 1 (suppl): S352, 1975Google Scholar
  74. 74.
    Gulyassy PF, Peters JH, Lin SC, Ryan PM: Hemodialysis and plasma amino acid composition in chronic renal failure. Am J Clin Nutr 21: 565, 1968PubMedGoogle Scholar
  75. 75.
    Sargent JA, Gotch FA, Borah MF, Piercy L, Spinozzi N, Schoenfeld PY, Humphreys MH: Urea kinetics: A guide to nutrition management of renal failure. Am J Clin Nutr 1978Google Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1979

Authors and Affiliations

  • John A. Sargent
  • Frank A. Gotch

There are no affiliations available

Personalised recommendations